India Glycols Q4 & FY26 Results: Revenue Up 11.8%, PAT Up 26.8%
India Glycols Limited reported Q4 FY26 results with Net Revenue up 13.1% to ₹976 Cr and PAT up 35.7% to ₹87 Cr. For FY26, Net Revenue grew 11.8% to ₹4,211 Cr and PAT increased 26.8% to ₹293 Cr. The company's demerger scheme application was admitted by NCLT, with a hearing on May 21, 2026.
The announcement details significant financial growth across key metrics and provides updates on a crucial corporate restructuring (demerger) which is expected to unlock stakeholder value and improve focus. These are material events for investors.
The company has reported strong growth in revenue, EBITDA, and PAT for both the quarter and the full year, indicating positive financial performance. The reduction in finance costs and surge in cash generation from operations further strengthen the positive sentiment.
India Glycols Limited (IGL) announced its financial results for the fourth quarter and full year ended March 31, 2026. The company reported a strong performance with Net Revenue increasing by 11.8% to ₹4,211 crore and EBITDA rising by 24.5% to ₹654 crore for FY26. Profit After Tax (PAT) saw a significant jump of 26.8%, reaching ₹293 crore.
For the fourth quarter of FY26, Net Revenue grew by 13.1% to ₹976 crore, while EBITDA increased by 13.3% to ₹167 crore. PAT for the quarter surged by 35.7% to ₹87 crore.
The company's performance was driven by broad-based growth across its segments. Potable Spirits (PS) delivered strong revenue growth of 14.4% YoY to ₹1,331 crore with an EBIT margin of 21.4%. Bio-Fuel also showed excellent growth, with revenue and margins up by 40.9% and 241 basis points respectively. The Bio-based Specialties & Performance Chemicals (BSPC) segment reported good EBIT growth of 12.5% with an EBIT margin of 11.7%, despite a revenue dip, as the company focuses on high-margin business. The EB segment reported strong growth in Q4FY26, up by 23.2% YoY, though margins remained under pressure.
Finance costs declined to ₹26 crore in Q4FY26 from ₹45 crore in Q4FY25 due to debt reduction. Cash generation from operations surged to ₹769 crore, an increase of 112.4% YoY in FY26.
IGL also provided an update on its proposed restructuring, where the application for the demerger scheme has been admitted by NCLT, with a further hearing scheduled for May 21, 2026. The company is strategically positioned for future financial performance, supported by its diverse product portfolio, operational efficiencies, and a focus on sustainability.
India Glycols Limited is a leading manufacturer of Bio-based Specialties & Performance Chemicals (BSPC), Bio-Fuel, Potable Spirits (PS) and Ennature Biopharma (EB). It is the first company in the world to produce Ethylene Oxide (EO) / Mono Ethylene Glycol (MEG) from renewable Agro route based on molasses since 1989.
What to do with a filing like this
India Glycols Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by India Glycols Limited. Read the original for the full detail.